Novartis Ag

Rainer Hillenbrand

Francois Legay

Peter Marbach

Severine Marrony

Patrick Albientz

Judith Schaefer

Jean-Michel Grenet

Yuan Gao

Mara Fornaro

Daniela Stoellner

John Xu

High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Antibodies to modified human IGF-1/E peptides

A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.

Drug monitoring assay

Growing community of inventors

Shanghai, China

Rainer Hillenbrand